Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
|Articles|January 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Merck and Idera to develop TLR9 agonists for treatment of cancer
Merck and Idera to develop TLR9 agonists for treatment of cancer
Advertisement
DARMSTADT, Germany-Merck KGaA has entered into a worldwide licensing and collaboration agreement, on behalf of its Merck Serono division, with Idera Pharmaceuticals of Cambridge, Massachusetts, for the research, development, and commercialization of Idera's toll-like receptor 9 (TLR9) agonists IMO-2055 and IMO-2125, and any follow-on TLR9 agonists identified through the collaboration.
Articles in this issue
almost 19 years ago
New tobacco product alert: Camel Snus is on the loosealmost 19 years ago
Blueberry punch not quite a 'knock out' blowalmost 19 years ago
Texas voters listen to Lancealmost 19 years ago
Cellectar opens manufacturing facility for radiolabeled CLR1404almost 19 years ago
High cost of breast MRI screening appears to be justifiedalmost 19 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskalmost 19 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caalmost 19 years ago
Statins during RT may lower risk of prostate ca relapseAdvertisement
Related to this article
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
4
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
5